Investors Helping Investors Beat the Market
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
For a minute there I thought the market was wising up. After spiking as high as 0.72 in advance of their 11/13/11 PDUFA for spurious buproprion reformulation CPI-300, the share price dumped immediately after the open last Friday on news that CPI-300 had been approved. I figured smart traders had registered the fact that IntelGenx is soon going to be the company of NO - no cash, no partner, no sales. The share price bottomed at 0.48 on Monday morning but today a strange event occurred - buying. I don't know who these geniuses were that took the share price to 0.575 today but I was happy to take my win and reverse the flow on this stock as promised.
Strong fundamentals here.. One of the cheapest Biotech Stock out there !
1) Very Very low Market cap of $23.5 M
2) Mega drug Pipeline of 9 Products including a potential Blockbuster
3) 2 New NDA filings in 2012
4) NO DEBT
5) Cash till 2014
6) Very strong Institutions and Insider in this stock holding over 50% of this Company
7) low float Stock
Intelgenx (IGXT.OB)
Market Cap : $26.1 M
Price: 0.56
Shares Out : 46 M (28 M shares held by Institutions and Insiders)
IntelGenx Announces FDA Approval of Its High Dose Anti-Depressant CPI-300
http://finance.yahoo.com/news/IntelGenx-Announces-FDA-pz-4172746127.html?x=0&l=1
Company Presentation
http://www.intelgenx.com/_assets/pdf/Intelgenx-Presentation.pdf
Ownership
http://data.cnbc.com/quotes/IGXT.OB/tab/8
interview with ceo
zerbe
http://www.cantechletter.com/2010/12/cantech-letter-interviews-horst-zerbe-president-and-ceo-of-intelgenx/
Article
http://www.biomedreports.com/2011111183312/fda-spproval-is-a-game-changer-for-intelgen
Upcoming Milestones
http://www.intelgenx.com/_assets/pdf/Intelgenx-FactSheet.pdf
Upcoming Milestones
•
Q4, 2011 Complete licensing agreement for CPI-300
•
Q4, 2011 Execute definitive agreement for new development and licensing VersaFilm project
•
Q4, 2011 Execute definitive agreement for bipolar disorder
•
Q4, 2011 Obtain FDA approval for CPI-300
•
Q2, 2012 Complete pivotal biostudy for anti-migraine VersaFilm
Please go back to Yahoo.